Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Intrinsic Value
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas i... [ Read More ]
The intrinsic value of one
EGRX
stock under the Base Case scenario is
43.42
USD.
Compared to the current market price of 4.77 USD,
Eagle Pharmaceuticals Inc
is
Undervalued by 89%.
Eagle Pharmaceuticals Inc's market capitalization is 62.5m USD.
EGRX stock price is 4.77 USD.
EGRX stock price (4.77 USD) is 89% less than its Intrinsic Value (43.42 USD).
EGRX stock price (4.77 USD) is 88% less than its Relative Value (40.06 USD). Open Relative Valuation
EGRX has upside potential of 256% compared to the average analyst price target.
Open Wall St Estimates
EGRX has positive three-year average ROIC (Return on Invested Capital): 10%. The company is efficient at using invested capital to generate operating income.
EGRX's ROE (Return on Equity) has decreased in the last 3 years from 8% to 5%.
EGRX's Revenue has dropped by 5% over the past 12 months.
EGRX's Altman Z-Score is equal to 2.61.
EGRX's ROIC (Return on Invested Capital) has decreased in the last 3 years from 9% to 4%.
EGRX's ROE (Return on Equity) for the past 12 months is very low and is equal to 5%.
EGRX's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 4%.
EGRX has positive Operating Income for the last twelve months.
EGRX has positive Net Income for the last twelve months.
EGRX has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
EGRX's Revenue has been growing by 13% per year for the last 3 years.
EGRX's Revenue is forecast to fall at a rate of 10% per year over the next 3 years.
EGRX generates enough operating income (36m USD) to cover interest payments on its debt (4m USD).
EGRX has negative Free Cash Flow for the last twelve months.
EGRX's short-term assets (187m USD) exceed its short-term liabilties (87m USD).
EGRX has positive Net Debt. This means that the company has more debt (62m USD) than cash and short-term investments (15m USD).
EGRX's long-term assets (405m USD) exceed its long-term liabilties (153m USD).
EGRX has positive Gross Profit for the last twelve months.
EGRX's D/E (Debt to Equity) is very low and is equal to 0.25.
Valuation Backtest
Eagle Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
EGRX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Eagle Pharmaceuticals Inc
Balance Sheet Decomposition
Eagle Pharmaceuticals Inc
| Current Assets | 187.3m |
| Cash & Short-Term Investments | 15.4m |
| Receivables | 116.3m |
| Other Current Assets | 55.6m |
| Non-Current Assets | 217.5m |
| PP&E | 1m |
| Intangibles | 152.4m |
| Other Non-Current Assets | 64.1m |
| Current Liabilities | 86.6m |
| Accounts Payable | 15.8m |
| Accrued Liabilities | 61.3m |
| Other Current Liabilities | 9.5m |
| Non-Current Liabilities | 66.2m |
| Long-Term Debt | 61.9m |
| Other Non-Current Liabilities | 4.3m |
Earnings Waterfall
Eagle Pharmaceuticals Inc
|
Revenue
|
257.5m
USD
|
|
Cost of Revenue
|
-77.6m
USD
|
|
Gross Profit
|
179.9m
USD
|
|
Operating Expenses
|
-143.8m
USD
|
|
Operating Income
|
36.1m
USD
|
|
Other Expenses
|
-24m
USD
|
|
Net Income
|
12.1m
USD
|
Free Cash Flow Analysis
Eagle Pharmaceuticals Inc
What is Free Cash Flow?
EGRX Profitability Score
Profitability Due Diligence
Eagle Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Eagle Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
EGRX Solvency Score
Solvency Due Diligence
Eagle Pharmaceuticals Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Eagle Pharmaceuticals Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EGRX Price Targets Summary
Eagle Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
EGRX
is 17 USD
.
Ownership
EGRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EGRX Price
Eagle Pharmaceuticals Inc
| Average Annual Return | -9.85% |
| Standard Deviation of Annual Returns | 27.35% |
| Max Drawdown | -93% |
| Market Capitalization | 62.5m USD |
| Shares Outstanding | 12 958 200 |
| Percentage of Shares Shorted | 14.47% |
Company Profile
Eagle Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 102 full-time employees. The company went IPO on 2014-02-12. The firm's commercialized products include Ryanodex, Bendeka, Belrapzo, Treakisym, and Pemfexy. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, Bendeka and Treakisym are used for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Pemfexy is an IV-administered cancer agent indicated for locally advanced or metastatic non-small cell lung cancer and mesothelioma. Its oncology and CNS/metabolic critical care pipeline includes product candidates that addresses underserved therapeutic areas across multiple disease states. Its vasopressin is an A-rated generic alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The company is engaged in clinical trials for CAL02, an approach to the treatment of severe bacterial pneumonia.
Contact
IPO
Employees
Officers
The intrinsic value of one
EGRX
stock under the Base Case scenario is
43.42
USD.
Compared to the current market price of 4.77 USD,
Eagle Pharmaceuticals Inc
is
Undervalued by 89%.
You don't have any saved screeners yet
